The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo

Z. Y. Yang, N. D. Perkins, T. Ohno, E. G. Nabel, G. J. Nabel

Research output: Contribution to journalArticlepeer-review

202 Scopus citations

Abstract

The p21 gene encodes a cyclin-dependent kinase inhibitor that affects cell-cycle progression, but the potential of this gene product to serve as a tumour suppressor in vivo has not been established. In this report, we show that the growth of malignant cells in vitro and in vivo is inhibited by expression of p27. Expression of p27 resulted in an accumulation of cells in G0/G1, altered morphology, and cell differentiation, but apoptosis was not induced. Introduction of p27 with adenoviral vectors into malignant cells completely suppressed their growth in vivo and also reduced the growth of established pre-existing tumours. Gene transfer of p27 may provide a molecular genetic approach to arresting cancer cell growth by committing malignant cells irreversibly to a pathway of terminal differentiation.

Original languageEnglish (US)
Pages (from-to)1052-1056
Number of pages5
JournalNature Medicine
Volume1
Issue number10
StatePublished - 1995
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint

Dive into the research topics of 'The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo'. Together they form a unique fingerprint.

Cite this